Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Other Accumulated Expenses: 2009-2024

Historic Other Accumulated Expenses for Lifecore Biomedical (LFCR) over the last 16 years, with May 2024 value amounting to $9.4 million.

  • Lifecore Biomedical's Other Accumulated Expenses rose 28.85% to $9.9 million in Q4 2024 from the same period last year, while for Nov 2024 it was $9.9 million, marking a year-over-year increase of 28.85%. This contributed to the annual value of $9.4 million for FY2024, which is 30.97% up from last year.
  • Lifecore Biomedical's Other Accumulated Expenses amounted to $9.4 million in FY2024, which was up 30.97% from $7.1 million recorded in FY2023.
  • In the past 5 years, Lifecore Biomedical's Other Accumulated Expenses registered a high of $10.0 million during FY2020, and its lowest value of $3.0 million during FY2021.
  • For the 3-year period, Lifecore Biomedical's Other Accumulated Expenses averaged around $7.7 million, with its median value being $7.1 million (2023).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first crashed by 69.84% in 2021, then soared by 115.32% in 2022.
  • Lifecore Biomedical's Other Accumulated Expenses (Yearly) stood at $10.0 million in 2020, then crashed by 69.84% to $3.0 million in 2021, then skyrocketed by 115.32% to $6.5 million in 2022, then climbed by 10.23% to $7.1 million in 2023, then spiked by 30.97% to $9.4 million in 2024.